Engineers Gate Manager LP Provention Bio, Inc. Transaction History

Engineers Gate Manager LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $121,048 - $437,402	18,067 Added 56.2%	50,215 $1.21 Million
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $145,308 - $339,804	32,148 New	32,148 $339,000
Q2 2022 Aug 15, 2022	SELL	$3.65 - $7.3 $60,225 - $120,450	-16,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.4 - $7.88 $56,100 - $130,020	16,500 New	16,500 $121,000
Q4 2021 Feb 14, 2022	SELL	$5.59 - $7.39 $63,552 - $84,016	-11,369 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $12,485 - $18,375	-2,206 Reduced 16.25%	11,369 $73,000
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $1,435 - $2,362	214 Added 1.6%	13,575 $114,000
Q1 2021 May 17, 2021	SELL	$10.12 - $19.45 $78,885 - $151,612	-7,795 Reduced 36.85%	13,361 $140,000
Q4 2020 Feb 16, 2021	BUY	$11.79 - $18.94 $249,429 - $400,694	21,156 New	21,156 $358,000
Q3 2020 Nov 16, 2020	SELL	$10.34 - $15.2 $498,232 - $732,412	-48,185 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$7.81 - $17.0 $376,324 - $819,145	48,185 New	48,185 $680,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.